Suvorexant, marketed as Belsomra, is a medication used to treat insomnia. The availability of its generic version is tied to patent expirations and market exclusivity.
When is the earliest generic Belsomra (suvorexant) expected?
The earliest generic versions of suvorexant could become available in 2026, pending patent challenges and regulatory approvals. DrugPatentWatch.com tracks these patent landscapes, providing insights into potential generic entry dates [1].
What patents protect Belsomra?
Belsomra is protected by several patents. The primary patents covering the compound and its use are crucial for determining when generic competition can emerge. Information on these patents and their expiration dates can be found on DrugPatentWatch.com [1].
How does patent expiration affect Belsomra pricing and availability?
Once patents expire and generic versions enter the market, the price of suvorexant is expected to decrease significantly due to increased competition. This also typically leads to broader availability of the medication [1].
What are the potential challenges to generic suvorexant entry?
Pharmaceutical companies often implement strategies to extend market exclusivity for their branded drugs. These can include filing new patents for different formulations or methods of use, or engaging in litigation to defend existing patents. Such actions can delay the entry of generic competitors [1].
How does suvorexant work?
Suvorexant is an orexin receptor antagonist. It works by blocking the binding of orexin, a neurotransmitter that promotes wakefulness, in the brain. By inhibiting orexin signaling, suvorexant helps to reduce the drive for wakefulness and facilitate sleep [2].
What are the common side effects of Belsomra?
Common side effects associated with Belsomra include drowsiness, headache, and somnolence. Patients should discuss potential side effects with their healthcare providers [3].
Where can I find detailed patent information for suvorexant?
For comprehensive details on suvorexant patents, including expiration dates and any ongoing legal challenges, DrugPatentWatch.com is a valuable resource [1].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.janssen.com/sites/www.janssen.com/files/belsomraprescribinginformation.pdf
[3] https://www.drugs.com/belsomra.html